Erin O’Boyle

Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron

Thomas Ottoboni, Mark Gelder, Erin O’Boyle · Journal of Experimental Pharmacology · 2014 · 39 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial

Harry Raftopoulos, William Cooper, Erin O’Boyle et al. · Supportive Care in Cancer · 2014 · 37 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation

Jay W. Mason, Thomas E. Moon, Erin O’Boyle et al. · Cancer Management and Research · 2014 · 19 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +9

Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials

C. Smith, Ronald Yanagihara, Marek Spaczyński et al. · Cancer Management and Research · 2015 · 18 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Slow-Release Granisetron (APF530) Versus Palonosetron for Chemotherapy-Induced Nausea/Vomiting: Analysis by American Society of Clinical Oncology Emetogenicity Criteria

Harry Raftopoulos, Ralph V. Boccia, William Cooper et al. · Future Oncology · 2015 · 14 citations

Medicine, Pharmacology, Pharmacotherapy +17